The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial
Abstract
Background: Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy (oHCM). Objective: To characterize the effect of mavacamten on left ventricular outflow tract (LVOT) gradient. Design: Open-label, nonrandomized, phase 2 trial. (ClinicalTrials.gov: NCT02842242). Setting: 5 academic centers. Participants: 21 symptomatic patients with oHCM. Intervention: Patients in cohort A received mavacamten, 10 to 20 mg/d, without background medications. Those in cohort B received mavacamten, 2 to 5 mg/d, with β-blockers allowed. Measurements: The primary end point was change in postexercise LVOT gradient at 12 weeks. Secondary end points included changes in peak oxygen consumption (pVO2), resting and Valsalva LVOT gradients, left ventricular ejection fraction (LVEF), and numerical rating scale dyspnea score. Results: In cohort A, mavacamten reduced mean postexercise LVOT gradient from 103 mm Hg (SD, 50) at baseline to 19 mm Hg (SD, 13) at 12 weeks (mean change, -89.5 mm Hg [95% CI, -138.3 to -40.7 mm Hg]; P = 0.008). Resting LVEF was also reduced (mean change, -15% [CI, -23% to -6%]). Peak VO2 increased by a mean of 3.5 mL/kg/min (CI, 1.2 to 5.9 mL/kg/min). In cohort B, the mean postexercise LVOT gradient decreased from 86 mm Hg (SD, 43) to 64 mm Hg (SD, 26) (mean change, -25.0 mm Hg [CI, -47.1 to -3.0 mm Hg]; P = 0.020), and mean change in resting LVEF was -6% (CI, -10% to -1%). Peak VO2 increased by a mean of 1.7 mL/kg/min (SD, 2.3) (CI, 0.03 to 3.3 mL/kg/min). Dyspnea scores improved in both cohorts. Mavacamten was well tolerated, with mostly mild (80%), moderate (19%), and unrelated (79%) adverse events. The most common adverse events definitely or possibly related to mavacamten were decreased LVEF at higher plasma concentrations and atrial fibrillation. Limitation: Small size; open-label design. Conclusion: Mavacamten can reduce LVOT obstruction and improve exercise capacity and symptoms in patients with oHCM. Primary Funding Source: MyoKardia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,104
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Maron, M. S., Olivotto, I., Betocchi, S., Casey, S. A., Lesser, J. R., Losi, M. A., Cecchi, F., & Maron, B. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021332 · Cited by 1,259
Clinical Course and Management of Hypertrophic Cardiomyopathy
Maron, B. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1710575 · Cited by 944
Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., Cirino, A. L., Fox, J. C., Lakdawala, N. K., Ware, J. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033200 · Cited by 860
Self-citationA small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
Green, E. M., Wakimoto, H., Anderson, R. L., Evanchik, M. J., Gorham, J. M., Harrison, B. C., Henze, M., Kawas, R., Oslob, J. D., Rodriguez, H. M., et al. (2016) · Science · doi:10.1126/science.aad3456 · Cited by 707
Monitoring clinical changes in patients with heart failure: A comparison of methods
Spertus, J., Peterson, E., Conard, M. W., Heidenreich, P. A., Krumholz, H. M., Jones, P., McCullough, P. A., Pina, I., Tooley, J., Weintraub, W. S., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.010 · Cited by 562
Anderson, R. L., Trivedi, D. V., Sarkar, S. S., Henze, M., Ma, W., Gong, H., Rogers, C. S., Gorham, J. M., Wong, F. L., Morck, M. M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809540115 · Cited by 405
Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
Sorajja, P., Valeti, U., Nishimura, R. A., Ommen, S. R., Rihal, C. S., Gersh, B. J., Hodge, D. O., Schaff, H. V., & Holmes, D. R. (2008) · Circulation · doi:10.1161/circulationaha.107.738740 · Cited by 310
Cited by
Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Self-citationOmmen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001250 · Cited by 807
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.045 · Cited by 643
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.04.018 · Cited by 42
Patel, N., Gaonkar, M., Pampana, A., Shetty, N. S., Vekariya, N., Li, P., Arora, G., & Arora, P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.01.003 · Cited by 2
Metadata
- Authors
- Heitner, S. B., Jacoby, D., Lester, S. J., Owens, A., Wang, A., Zhang, D., Lambing, J., Lee, J., Semigran, M., & Sehnert, A. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-06-04
- Volume
- 170
- Issue
- 11
- Pages
- 741-748
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2942611143
- Cited by
- 303
- References
- 24
- FWCI
- 18.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. https://app.cochat.ai/papers/10.7326/m18-3016
- The paper
- Heitner, S. B., Jacoby, D., Lester, S. J., Owens, A., Wang, A., Zhang, D., Lambing, J., Lee, J., Semigran, M., & Sehnert, A. J. (2019). Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Annals of Internal Medicine. https://doi.org/10.7326/m18-3016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.